Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1717095

	registered interest
	date	10/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ritlecitinib: Shropshire
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when she expects Litfulo to be made available to NHS patients in (a) Shropshire, (b) Telford and (c) Wrekin.
	tabling member constituency	The Wrekin
	tabling member printed	Mark Pritchard
	uin	25645
	answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations on whether all new licensed medicines should be routinely funded by the National Health Service, based on an assessment of their costs and benefits.</p><p>On 27 March 2024, NICE published final technology appraisal guidance recommending ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years old and over. The NHS in England is legally required to fund medicines recommended by NICE within three months of the publication of its final guidance.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 14/05/2024 16:53:44 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1576 label Biography information for Mark Pritchard

1717152

	registered interest
	date	10/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Operating Costs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the annual running costs were for NHS (a) Arden and GEM, (b) Midlands and Lancashire, (c) North of England and (d) South, Central and West Commissioning Support Unit in the 2022-23 financial year.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	25658
	answer	answer is ministerial correction date of answer // answer text <p>The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered // answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1717158

	registered interest
	date	10/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Joint Replacements: Post-operative Care
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department has made a recent assessment of the potential merits of adopting the (a) Infection & Orthopaedic Management (INFORM), (b) British Orthopaedic Association and (c) other guidelines for the treatment and management of prosthetic joint infections.
	tabling member constituency	Hayes and Harlington
	tabling member printed	John McDonnell
	uin	25603
	answer	answer is ministerial correction date of answer 17/05/2024 answer text <p>The UK Health Security Agency manages a national surveillance programme, the Surgical Site Infection (SSI) Surveillance Service, which enhances the quality of patient care by providing hospitals with a framework for collection and comparison of their rates of SSI against national benchmarks. This information is used to review and guide clinical practice, to reduce the risk of infection following surgery. Hip and knee replacements are two of the 17 categories of surgery under surveillance by hospitals. Surveillance in at least one orthopaedic surgical category per quarter, per financial year is mandatory for all National Health Service hospitals undertaking orthopaedic surgery, with hip and knee replacements being the most numerous.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/05/2024 11:48:26 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	178 label Biography information for John McDonnell

1717159

	registered interest
	date	10/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Joint Replacements: Post-operative Care
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help tackle post-operative infections in the context of (a) an ageing population and (b) trends in the number of joint replacement operations.
	tabling member constituency	Hayes and Harlington
	tabling member printed	John McDonnell
	uin	25604
	answer	answer is ministerial correction date of answer 16/05/2024 answer text <p>The UK Health Security Agency manages a national surveillance programme, the Surgical Site Infection (SSI) Surveillance Service, which enhances the quality of patient care by providing hospitals with a framework for collection and comparison of their rates of SSI against national benchmarks. This information is used to review and guide clinical practice to reduce the risk of infection following surgery. Hip and knee replacements are two of the 17 categories of surgery under surveillance by hospitals. Surveillance in at least one orthopaedic surgical category per quarter, per financial year is mandatory for all National Health Service hospitals undertaking orthopaedic surgery, with hip and knee replacements being the most numerous.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/05/2024 13:55:11 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	178 label Biography information for John McDonnell

1717160

	registered interest
	date	10/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Joint Replacements: Post-operative Care
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that best practice guidelines for prosthetic infection are implemented across elective surgery clinical care pathways.
	tabling member constituency	Hayes and Harlington
	tabling member printed	John McDonnell
	uin	25605
	answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>The Government is working with NHS England to improve perioperative care. This should ensure best practice guidelines are implemented across surgery clinical care pathways, including for prosthetic infections. In May 2023, NHS England published guidance setting out five core perioperative care requirements relating to the care of adult patients awaiting planned inpatient surgery. These measures address the key objective of identifying health needs as early as possible in perioperative pathways, and then using time on the waiting list to optimise health. The NHS England National Elective Recovery and Outpatients programme is working with NHS England regional teams to help oversee and support compliance, and will continue to do so throughout 2024/25.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 14/05/2024 16:56:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	178 label Biography information for John McDonnell

1717162

	registered interest
	date	10/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer and Joint Replacements: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential merits of expanding the holistic care approach for cancer (a) care and (b) delivery to (i) prosthetic infection and (ii) other clinical conditions.
	tabling member constituency	Hayes and Harlington
	tabling member printed	John McDonnell
	uin	25607
	answer	answer is ministerial correction date of answer 16/05/2024 answer text <p>The Department has not made a formal assessment of the merits of expanding the holistic approach, used for cancer, to prosthetic infection and other clinical conditions, however the National Health Service is working towards a holistic approach in infection prevention and control, and in long-term conditions. This includes improving perioperative care for surgical clinical care pathways, including for prosthetic infections, whereby patients receive proactive, personalised support to optimise their health before surgery.</p><p>The NHS works hard to deliver care to meet people’s needs as far as possible, given this can have a significant impact on their experience and quality of life. Cancer Alliances across England are working to ensure that every person receives personalised care and support from cancer diagnosis onwards. This involves holistic need assessments to ensure people's physical, practical, emotional, and social needs are identified and addressed at the earliest opportunity. It also involves accessible information about emotional support, coping with side effects, financial advice, getting back to work, and making healthy lifestyle choices, before, during, and after treatment.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/05/2024 13:51:44 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	178 label Biography information for John McDonnell

1717172

	registered interest
	date	10/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Thalassaemia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England on the introduction of (a) gene therapy and (b) other new treatments for patients with thalassaemia.
	tabling member constituency	Enfield, Southgate
	tabling member printed	Bambos Charalambous
	uin	25665
	answer	answer is ministerial correction date of answer 16/05/2024 answer text <p>The Department regularly discusses a range of issues with colleagues in NHS England related to patient access to new medicines. The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether all new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE’s appraisal of the gene therapy, exagamglogene autotemcel, for treating transfusion-dependent beta-thalassaemia is currently paused, to allow the company and NHS England to enter into commercial and managed access discussions.</p><p>In November 2023, NHS England published a clinical commissioning policy that recommends that allogeneic haematopoietic stem cell transplantation for adult transfusion dependent thalassaemia should be routinely commissioned.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/05/2024 13:59:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4610 label Biography information for Bambos Charalambous

1717175

	registered interest
	date	10/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Defibrillators
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of access to defibrillators.
	tabling member constituency	Oxford West and Abingdon
	tabling member printed	Layla Moran
	uin	25679
	answer	answer is ministerial correction date of answer 16/05/2024 answer text <p>To improve survival rates for out-of-hospital cardiac arrest cases, the Government launched a new £1 million one-off fund that will expand community access to Automated External Defibrillators (AEDs). The grant was made available from September 2023.</p><p>We estimated 1,000 new defibrillators would be provided by the fund, with the potential for this to double, as most applicants would be asked to match the funding they receive partially or fully. To date, the grant has successfully delivered 2,000 AEDs.</p><p>Research has shown that those in the most deprived areas of England had to travel over one kilometre to their nearest accessible, nonstop service public access defibrillator, which tended to be 99.2 metres further away than in the least deprived areas.</p><p>Applications for AEDs are selected in line with criteria to provide AEDs where there is greatest need. The criteria include remote communities with extended ambulance response times, places with high footfall and high population densities, hotspots for cardiac arrest including sporting venues and venues with vulnerable people, and deprived areas.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/05/2024 08:33:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4656 label Biography information for Layla Moran

1716801

	registered interest
	date	09/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medicine: Education
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will hold discussions with the (a) Medical Schools Council and (b) British Medical Association on the effectiveness of preference-informed allocation for foundation placements for medical graduates.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	25505
	answer	answer is ministerial correction date of answer 15/05/2024 answer text <p>The UK Foundation Programme Office (UKFPO) manages the national application process for the UK Foundation Programme, on behalf of the four statutory education bodies for the United Kingdom. The UKFPO changed the allocation process for the programme this year to a Preference Informed Allocation method. This consisted of applicants being given a computer-generated rank, and removed the requirement for them to sit the Situational Judgement Test. This change was based on engagement with stakeholders, including the Medical Schools Council, and the British Medical Association.</p><p>When confirming the move to the new system last year, the UKFPO set out that once implemented, it would be kept under constant review, to make sure it is working well for applicants. The UKFPO has confirmed that 75% of applicants received their first choice of programme this year, a 4% increase on last year.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/05/2024 15:44:06 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1716806

	registered interest
	date	09/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pancreatic Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of the availability of enzyme replacement therapy.
	tabling member constituency	Jarrow
	tabling member printed	Kate Osborne
	uin	25591
	answer	answer is ministerial correction date of answer 15/05/2024 answer text <p>We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 25370 25371 question first answered 15/05/2024 08:18:01 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4783 label Biography information for Kate Osborne